GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Peter Lynch Fair Value

CardieX (ASX:CDX) Peter Lynch Fair Value : N/A (As of Dec. 15, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CardieX Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for CardieX's Peter Lynch Fair Value or its related term are showing as below:



ASX:CDX's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.78
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


CardieX Peter Lynch Fair Value Historical Data

The historical data trend for CardieX's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardieX Peter Lynch Fair Value Chart

CardieX Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CardieX Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CardieX's Peter Lynch Fair Value

For the Medical Devices subindustry, CardieX's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CardieX's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CardieX's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where CardieX's Price-to-Peter-Lynch-Fair-Value falls into.



CardieX Peter Lynch Fair Value Calculation

CardieX's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-0.132
=N/A

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CardieX's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.13.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


CardieX  (ASX:CDX) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

CardieX's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.099/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CardieX Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of CardieX's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CardieX Business Description

Traded in Other Exchanges
N/A
Address
55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000
CardieX Ltd is a health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX Headlines

No Headlines